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Primary fallopian tubecarcinoma(PFTC) is a raregynecologicalmalignancywith the followingcharacteristics:
its preoperativediagnosis is easy tomissordelaybecauseof a lackof speciﬁc symptomsandsigns; it isdifﬁcult
to distinguish from serous epithelial ovarian cancer or primary peritoneal serous carcinoma during or even
after operation because they have the samehistopathological features; and there is uncertainty regarding the
optimalmanagement becauseof the lackof available standard guidelines. All of these factors contribute to the
major challenge of undertaking a comprehensive study of this disease. To improve our understanding of this
rare disease, the domestic data were summarized ﬁrst. We searched PubMed on this topic, using the term
“primary fallopian tube tumor and Taiwan” (from January 1, 1990 to November 3, 2013) and identiﬁed 15
published articles, but only 11 studies focused on the outcome of patients with PFTC in Taiwan. These limited
datawere not enough to increase our knowledge in dealingwith this disease; therefore, the addition of large
series or published review articles addressing this topic was needed. According to these reports, we
concluded: (1) themain type of PFTCwas serous type, oftenpoorly differentiated; (2) the diagnosis of PFTC is
frequently missed or delayed; (3) PFTC is often of an earlier International Federation of Gynecology and
Obstetrics (FIGO) stage than is epithelial ovarian cancer (EOC), because of the appearance of earlier but
nonspeciﬁc symptoms or signs, such as abdominal pain, vaginal bleeding, and watery discharge or mass; (4)
the most important clinicopathological prognostic factor was FIGO stage; (5) the therapeutic strategy is still
uncertain, but is oftenbased on the guidelines for treating EOC. An intensive surgical effort such as a complete
surgical resection or optimal cytoreduction surgery with a minimal residual tumor followed by a platinum-
paclitaxel combination chemotherapy with/without targeted therapy (for example, antiangiogenesis
agents) may provide the best possibility of disease-free or overall survival.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.s and Gynecology, National
terans General Hospital, 201,
en), phwang@vghtpe.gov.tw,
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Primary fallopian tube carcinoma (PFTC) is a very rare gyneco-
logic malignancy, even though its true incidence may beby Elsevier Taiwan LLC. All rights reserved.
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or pathological features as serous-type epithelial ovarian carci-
noma (EOC) or primary peritoneal serous carcinoma (PPSC) [1,2].
Treatment is normally based on the same guidelines as those used
for EOC, because PFTC tends to spread intraperitoneally. However,
there is no doubt that the optimal management of PFTC is still
uncertain, because of the rarity of the disease. Although PFTC is
very similar to serous-type EOC, there are still a few differences
between the two. For example, PFTC tends to recur in the retro-
peritoneal nodes and distant sites more than does EOC [3]. PFTC is
more frequently found at an early stage, but EOC is often diagnosed
at an advanced stage [1]. Abdominal pain is often found in patients
with PFTC, because tubal distension may result in this nonspeciﬁc
symptom [1]. The shorter history of symptoms in PFTC than in EOC
allows detection at an earlier stage in patients with PFTC [4]. PFTC
shows a propensity for microscopic distant metastases, compared
with the macroscopic intraperitoneal metastasis of EOC [5].
Similar to EOC [6,7], complete surgical staging in early-stage
[International Federation of Gynecology and Obstetrics (FIGO)
stage I/II] PFTC and extensive and optimal debulking surgery in late-
stage (FIGO III/IV) PFTC, including cytology, total hysterectomy,
bilateral salpingo-oophorectomy, retroperitoneal lymph node
dissection, appendectomy, omentectomy, and excisional biopsy for
all suspicious lesions, provided the best chance of cure. However,
becauseof thepropensityof PFTC formicroscopicdistantmetastases
and the relatively high risk of recurrence despite complete tumor
excision in the early stage, postoperative chemotherapy was highly
recommended [8,9], although some opposed this suggestion [1].
In an earlier report [9], we found that two Stage IA patients
without adjuvant chemotherapy had died of the disease: one expe-
rienced recurrence 765 days after completion of the surgery and the
other, 1012 days postsurgery. Although complete and thorough sur-
gical intervention for Stage I PFTC is important, some authors did not
favor the use of postoperative adjuvant therapy, especially in Stages
IA and IB disease without tumor inﬁltration of the serosa or without
pre- or intra-operatively ruptured tumors [1]. Even so, we suggest
that postoperative adjuvant chemotherapymay play a crucial role in
the successfulmanagementof surgicopathological Stage I PFTA, even
in Stage IA cases; especially if the tumor size is>2 cm indiameter [8].
Another study included 25 patients with complete staging for PFTC,
followed by multiagent chemotherapy [9]. In that report, even
though 44% of patientswith PFTC (n¼ 11)were early stage andmore
than 90% of patients (n ¼ 9) received postoperative combination
chemotherapy [cyclophosphamide, adriamycin, and cisplatin], the
prognosis was still poor. The cumulative disease-free survival rate
wasonly36% [9]. Becauseof thepooroutcomesandtherarityofPFTC,
we believe it is necessary to review this topic to improve our un-
derstanding of this rare disease. We summarized all domestic data
andupdated the informationasa reference for futuremanagementof
this rare but relatively lethal disease.
Literature review
We searched PubMed on this topic, using the term “primary
fallopian tube tumor and Taiwan” (from January 1, 1990 to
November 3, 2013), and identiﬁed only 15 published articles
[9e23]; however, 11 studies discussed patients with PFTC in Taiwan
[9e19]. In addition, only three papers showed a series of case
studies [10e12], with patient numbers ranging from 12 to 25. To
further update our knowledge of this rare disease, other large series
were also included in this review [4,8,24e48].
The domestic data, including the three papers, were obtained
from two institutions, and data from larger series of patients with
PFTC (> 30 patients), including published review articles, are
summarized in Table 1.Clinical presentation
Because PFTC is often asymptomatic, a speciﬁc preoperative
diagnosis is extremely difﬁcult, and the usual clinical diagnosis is an
ovarian tumor or pelvic inﬂammatory disease (PID) [1]. The most
common symptoms and signs are abdominal pain, which may be
colicky as a result of forced tubal peristalsis or dull as a result of
tubal distension, and vaginal bleeding or watery discharge [1].
These symptoms or signs might allow for an earlier stage of PFTC to
be diagnosed. In addition, in patients who complain of lower
abdominal pain in association with vaginal bleeding and/or watery
discharge (16.7%) or tubo-ovarian abscess (25%), the possibility of
PFTC should be considered [11]. However, the incidence of PID is
deﬁnitely far higher than that of PFTC, and PID is a medical illness
usually treated conservatively with antibiotics, not surgery [49,50].
The domestic data (Table 1) showed that although abdominal
pain might be one of the most frequently noted symptoms (> 50%),
fewer than 50% of all patients with PFTC were found at an earlier
stage (FIGO I/II) [9]. By contrast, abdominal pain, vaginal bleeding
or discharge, or even a pelvic mass seemed to be similarly
frequently reported in studies from Western countries (Table 1),
but in more than 50% of patients with PFTC the diagnosis was made
at an earlier stage (FIGO I/II). The Latzko triad of symptoms,
including an intermittent, profuse, serosanguinous vaginal
discharge, a colicky pain, often relieved by the discharge, and
abdominal or pelvic masses, has been reported in  15% of patients
with PFTC [1].
An early cervicovaginal cytological diagnosis in cases of silent
PFTC is a more difﬁcult issue [51], although cervicovaginal smears
might reveal cases of otherwise unsuspected PFTC. The anatomical
site of PFTC allows an early diagnosis by cervicovaginal smear,
because the malignant cells, which may exfoliate from the primary
tumors, migrate through the fallopian tube and are deposited in the
vaginal pouch or cervix canal. Some characteristic features of cer-
vicovaginal smears might suggest the possibility of PFTC; these
include the clean background, which disappears when liquid-based
cytology is used, the small number of malignant cells, and the
papillary grouping of overlapped neoplastic cells [52]. Moreover,
the lack of tumor diathesis appears to be an intriguing and almost
constant, although nonspeciﬁc, ﬁnding [50].
Imaging evaluation
Imaging routinely carried out for any suspicious gynecologic
cancers includes ultrasound, computed tomography (CT), and
magnetic resonance imaging (MRI) [53]. PFTC is difﬁcult to di-
agnose radiologically, and most cases are preoperatively diagnosed
as ovarian carcinomas [54]. Several single case reports in the
literature [55,56], including ours [17], describe the ultrasound, CT,
and MRI ﬁndings of PFTC.
Ultrasound is an essential imaging technique in the diagnostic
workup of patients with gynecological lesions, including PFTC.
Anechoic or low-level echoes with papillary projections or intra-
luminal masses revealed on ultrasound is an indication of PFTC;
however, most of the echographic appearances of the fallopian tube
are nonspeciﬁc, mimicking other pelvic diseases such as tubo-
ovarian abscess, ovarian tumor, and ectopic pregnancy [53]. The
appearance of PFTC is usually based on the dominant compo-
nentdthe solid tumor or the hydrosalpinx, which may be altered
with serial imaging, reﬂecting the change in the amount of serous
ﬂuid within the tube. The former appears as a sausage-shaped
adnexal mass and the latter appears as a ﬂuid-ﬁlled tubular
adnexa structure, containing nodular or papillary solid compo-
nents, or a multilocular cystic mass with a cog-and-wheel
appearance [57].
Table 1
Studies of primary fallopian tube carcinoma, including domestic data.
Study No./Age S/S (%) Stage (%) Factors F-U 5-y DFSR or 5-y OSR, moa (%)
Lau et al (2013) [11] 16/63 Pain (50); Mass (69) I/II (31); III/IV (69) CSRb 40 73 (95 mo)
Ou et al (2011) [12] 12/54 Mass (50) I/II (50); III/IV (50) Stage 38 64
Wang et al (1998) [10] 25/57 Pain (48) I/II (44); III/IV (56) NA 89 36
Pectasides et al (2009) [4] 64/61 NA I/II (45); III/IV (55) Stage, CSR 40 (70, all); 62 (I/II); 38 (III/IV)
Rosen et al (1994) [8] 68/60 P (NA) I (74); II (26) Grade, age 72 24 (51, all)
Rose et al (1990) [24] 40/NA P (48) NA 2nd - look 91 28 (15, all)
Barakat et al (1993) [25] 35/NA NA I/II (23); III/IV (75) CSR 50 (19, all)
Hellstr€om et al (1994) [26] 128/56 NA I/II (74); III/IV (26) Stage, grade, C/T NA NA
Pfeiffer et al (1989) [27] 52/60 P (69); V (62) I/II (67); III/IV (33) Stage; LN 46 22 (37, all); (64, I); (40%, II); (6, III/IV),
Rosen et al (1994) [28] 66/62 NA I/II (55); III/IV (45) Stage NA 29 (all); 65 (50, I/II); 24 (14, III/IV)
Zheng et al (1997) [29] 52/NA NA I/II (17); III/IV (56) Stage, p53 42 (19, all)
Vaughan et al (1998) [30] 37/57 V (46); P (32) I/II (73); III/IV (27) Stage NA 37 (37, all); 78 (69, I); 40 (26, II); 9 (0, III)
Wolfson et al (1998) [31] 72/61 NA I/II (61); III/IV (39) Stage 48 (45, OSR); (27, DFSR)
Rosen et al (1999) [32] 143/63 NA I/II (61); III/IV (39) Stage, grade, CSR 29 48 (59, I/II); 28 (19, III/IV); (43, all)
Klein et al (1999) [33] 158/NA NA NA CSR 42 43 vs. 21 (III, LND vs. - LND)
Alvarado-Cabrero et al (1999) [34] 105/59 V (38); M (24) I/II (75); III/IV (25) Stage NA NA
Rosen et al (2000) [35] 63/61 NA I/II (56); III/IV (44) Stage NA 45 (43, all); 137 (59, I/II); 21 (19, III/IV)
Klein et al (2000) [36] 95/NA NA I (69); II (31) CSR NA (83 vs. 58 by CSR)
Heﬂer et al (2000) [37] 53/65 NA I/II (43); III/IV (57) Stage, marker NA (60, all)
Baekelandt et al (2000) [38] 151/61 P (50); M (69) I/II (54); III/IV (46) NA NA (73, all)
Obermair et al (2001) [39] 36/59 V (42); P (39) I (55); II/III/IV (45) CSR, stage 70 68 (58, all)
Gadducci et al (2001) [40] 88/59 P (34); V (32); M (66) I/II (47); III/IV (53) Stage, CSR, age NA 56 (57, all)
Klein et al (2002) [41] 41/62 NA I/II (54); III/IV (46) Stage, LN NA NA
Kosary et al (2002) [42] 416/NA NA I/II (31); III/IV (49) NA NA (95, I); (75, II); (69, III); (45, IV)
Heintz et al (2003) [43] 176/NA NA I/II (52); III/IV (46) NA NA (56, all)
Riska et al (2006) [44] 60/61 NA I/II (25); III/IV (75) Grade, marker NA 29 (33, all)
Moore et al (2007) [45] 96/58 NA I/II (52); III/IV (48) NA NA (26, 3-y DFSR)
(59, 3-y OSR)
Wethington et al (2008) [46] 1576/NA NA I/II (47); III/IV (50) Age, stage, CSR NA (64, all); (81, I; 65, II; 54, III)
Shamshirsaz et al (2011) [47] 36/69 P (19); M (14) I/II (61); III/IV (39) Stage, laterality, marker 40 (34, all)
Alvarado-Cabrero et al (2013) [48] 127/64 V (58); P (42); M (39) I/II (72); III/IV (28) Stage NA (56, all); (62, I); 16, II); (7, III) (0, IV)
Age¼mean or median age in years; CSR¼ complete surgical resection, including the absence of gross residual disease or similar to fewer and smaller-sized residual tumors or
achievement of optimal debulking surgery; C/T ¼ postoperative adjuvant multiagent chemotherapy; F-U¼mean or median follow-up (months); Factors¼ prognostic factors;
5-Y DFSR ¼ 5-year disease-free survival rate; 5-Y OSR ¼ 5-year overall survival rate; Grade ¼ cellular differentiation, including good, moderate and poor differentiation;
LN¼ lymph nodemetastases or lymphovascular invasion; LND¼ lymphadenectomy; M (Mass)¼ abdominal or pelvic or adnexamass; Marker¼ preoperative serummarkers,
such as carbohydrate antigen (CA) 125 and human chorionic gonadotropin beta; NA ¼ no data available; No. ¼ number of patients; P (Pain) ¼ abdominal pain, fullness or
gastrointestinal symptoms; S/S ¼ most common symptom and signs; 2nd-look ¼ negative laparotomy, including second-look or third-look, similar to CSR;
Stage ¼ International Federation of Gynecology and Obstetrics [FIGO] stage; V (VB & VD) ¼ vaginal bleeding and/or vaginal discharge.
a median or mean.
b review articles.
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pelvic soft tissue, but enhances less than the myometrium [54]. A
solid papillary intratubal mass allows for easy prediction of PFTC
[58]. With regard to MRI, we reported a case of preoperatively
diagnosed PFTC based on a high degree of suspicion [premeno-
pausal woman, vaginal spotting and watery discharge, and no
apparent adnexal mass and no dysmenorrhea, but an elevated
serum level of carbohydrate antigen (CA) 125], and typical MRI
featuresdthe solid tumor component of the PFTC was homoge-
neously or heterogeneously isointense or hyperintense on T2-
weighted images, hypointense on T1-weighted images, and
demonstrated enhancement after intravenous administration of
gadolinium-diethylene-tetraamine pentaacetic acid (Gd-DTPA)
[17], hyperintensity on T2-weighted images, and hypointensity or
hyperintensity of hemorrhage on T1-weighted images of the
hydrosalpinx component [57,58].Tumor markers
Many tumor markers have been reported to be valuable pre-
operatively to increase diagnostic accuracy and postoperatively to
monitor the response after treatment or detect tumor recurrence
during follow-up. CA 125 was the most commonly used, and is
often expressed by PFTC/ 80% of patients with PFTC have
elevated pretreatment serum levels of CA 125 [54]. Heﬂer et al [37]
reported that the median serum CA 125 in patients with PFTC
preoperatively was 183 U/mL, and found that the sensitivity,speciﬁcity, positive predictive value, and negative predictive value
of serum CA 125 levels in the follow-up of patients with PFTC were
92%, 90%, 67%, and 98%, respectively. In addition, the serum CA 125
level was found to correlate independently with disease-free
survival and overall survival of patients with PFTC [37,47],
adequately reﬂect patient response to chemotherapy, and precede
the clinical or radiologic diagnosis of recurrent disease in 90% of
patients with a median lead time of 3 months (range, 0.5e7
months) [37].
Another markerdthe beta-subunit of human chorionic gona-
dotropindhas also been reported to be a prognostic factor inde-
pendent of stage and histology in patients with PFTC [44]; however,
no further study has reconﬁrmed this ﬁnding.Pathology
Cases were deﬁned as patients identiﬁed as having PFTC per
diagnostic criteria established by Hu et al [59] and revised by
Sedlis [60,61]. The criteria are as follows: (1) the main tumor
arises from the endosalpinx; (2) the histological pattern re-
produces the epithelium of the tubal mucosa; (3) the transition
from benign to malignant tubal epithelium is demonstrable;
and (4) the ovaries or endometrium are either normal or contain
a tumor that is smaller than the tumor in the tube. More than
90% of PFTC was papillary serous adenocarcinoma, which is
graded with respect to differentiation and amount of solid
components [1].
Table 2
International Federation of Gynecology and Obstetrics stage of primary fallopian tube carcinoma.
Stage (TNM)
0 (Tis) Carcinoma in situ
I (T1) Carcinoma conﬁned in the fallopian tubes
IA (T1a) Tumor conﬁned to one tube without inﬁltrating the serosal surface
IB (T1b) Tumor conﬁned to both tubes without inﬁltrating the serosal surface
IC (T1c) Tumor conﬁned to one or both tubes while inﬁltrating the serosal surface or with positive malignant cells in the ascites or positive
peritoneal washing
II (T2) Tumor involving both tubes with pelvic extension
IIA (T2a) Tumor extension and/or metastases to uterus and/or ovary
IIB (T2b) Tumor extension to other pelvic organs
IIC (T2c) Stage IIA or IIB with positive malignant cells in the ascites or positive peritoneal washing
III (T3 and/or N1) Tumor involving one or both tubes with peritoneal implants outside the pelvis and/or positive regional lymph nodes
IIIA (T3a) Microscopic peritoneal metastases outside the pelvis
IIIB (T3b) Macroscopic peritoneal metastases outside the pelvis  2 cm in greatest dimension
IIIC (T3c and/or N1) Macroscopic peritoneal metastases outside the pelvis > 2 cm in greatest dimension and/or positive regional lymph nodes
IV (M1) Distant metastases beyond the peritoneal cavity. Positive pleural cytology and/or liver parenchymal metastases
TNM ¼ tumor, nodes, and metastases system.
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PFTC spreads in much the same manner as EOC, principally by
the transcoelomic exfoliation of cells that implant throughout the
pelvic and peritoneal cavity [3]. However, as mentioned previously,
PFTC seems to be more frequently detected in an earlier stage than
does EOC. In general, > 50% of patients with PFTC had Stages I and II
disease (Table 1). Domestic data seemed to support the equal dis-
tribution of earlier and advanced stages of PFTC (50% vs. 50%,
Table 1); early-stage EOC was also common in Taiwan [62e65].
Therefore, the distribution of early-stage EOC or PFTC seemed to be
similar in the domestic data. Data from the literature review indi-
cated that patients with PFTC have a higher rate of retroperitoneal
and distant metastases than those with EOC [1,3]. PFTC is richly
permeated with lymphatic channels that drain into the para-aortic
lymph nodes through infundibulopelvic lymphatics, with involve-
ment in 33% of patients with all stages of disease [66], and almost
equal involvement of the para-aortic and pelvic lymph nodes [54].
Because lymph nodemetastases are common in patients with PFTC,
lymphadenectomy is highly recommended for these patients. Klein
et al [33] found that radical lymphadenectomy increased the me-
dian survival to 43 months [95% conﬁdence interval (CI) 20e66],
compared to 21 months (95% CI 10e32) without lymphadenec-
tomy, suggesting that radical lymphadenectomy in tumors of equal
size may markedly prolong survival.
Koo et al [67] further found that selective pelvic or para-aortic
lymphadenectomy could miss lymph node involvement and lead
to an error in staging, suggesting that comprehensive retroperito-
neal lymphadenectomy, including both para-aortic and pelvic
lymphadenectomy, would be an important procedure, based on the
ﬁndings that the rates of isolated pelvic and para-aortic lymphatic
metastases were 2.4% and 22.0%, respectively. Furthermore, Def-
ﬁeux et al [68] suggested that the left para-aortic chain above the
level of the inferior mesenteric artery was the site that was most
frequently involved, even when the fallopian tubal cancer was on
the opposite side, although the authors did not provide good rea-
sons for this. It is possible that many of the Stage I patients were
understaged in an older series because of the lack of surgical
retroperitoneal assessment, which resulted in aworse prognosis for
these patients.
The staging of PFTC is based on the FIGO EOC staging system,
which requires a complete surgical approach (Table 2). Many pub-
lished articles have suggested that the FIGO stage is the most
important independent prognostic factor for patients with PFTC
(Table 1). Kosary and Trimble [42] used the National Cancer In-
stitute's Surveillance, Epidemiology, and End Results program to
identify 416 patients with PFTC, and found that 5-year survival byFIGO stage was as follows: Stage I (n ¼ 102), 95%; Stage II (n ¼ 29),
75%; Stage III (n¼ 52), 69%; Stage IV (n¼ 151), 45%.Wethington et al
[46] also reported similarﬁndings: the5-year survival rate for Stage I
tumors was 81%, and cancer-speciﬁc survival was 65% (95% CI
57e75) and 54% (95% CI 48e60) for Stages II and III, respectively. As
such, the reported survival for Stages I and II diseases has ranged
from37% to95%, and for Stages III and IV tumors, from0% to69% [46].
Treatment
Complete removal of the tumor is the goal of standard therapy
for PFTC, similar to the surgical management of EOC [69e73]. In
addition to FIGO stage, complete resection with no or minimal re-
sidual tumors has also been reported to be the most important
independent prognostic factor for both disease-free survival and
overall survival (Table 1). Complete resection is emphasized only
for advanced-stage PFTC. However, even in early-stage PFTC,
complete resection of the tumor is also important [1]. Klein et al
[36] found that complete resection, including additional radical
lymphadenectomy, provided a remarkably better 5-year survival
rate of 83%, whereas patients with total hysterectomy and bilateral
salpingo-oophorectomy achieved a 5-year survival rate of only 58%
(p ¼ 0.12). In addition, neither chemotherapy nor irradiation
signiﬁcantly beneﬁtted overall survival (p ¼ 0.813 for patients with
total hysterectomy and bilateral salpingo-oophorectomy; p ¼ 0.795
for those with additional lymphadenectomy) [36]. The possible
reason is the prognostic value of correct staging, which maintains
that the FIGO stage is the most important classic prognostic factor
in PFTC. Thus, as shown earlier in this article, surgery without
lymphadenectomymay result in underestimating the clinical stage;
i.e., some of the cases graded as Stages I or II during operation
should really be classiﬁed as Stage IIIC, because metastases of the
lymph nodes must be expected in as many as 30% of cases intra-
operatively staged as Stage II [33].
The high proportion of lymph node metastases makes PFTC
appear to be a generalized systemic disease, even in early-stage
PFTC, or FIGO Stage I PFTC, and this makes the intensiﬁed use of
chemotherapy altogether plausible [36]. However, some authors
considered that Stages IA and IB disease may not require extra
adjuvant treatment (as for patients with EOC), except early-stage
patients with tumors inﬁltrating the serosa or with preopera-
tively or intraoperatively ruptured tumors, who should receive
chemotherapy [1]. In our previous study on surgicopathological
Stage I PFTC, which supported the concept of Rosen et al [32] that
patients with FIGO IA PFTC, in particular, should receive adjuvant
treatment, we found that the trend toward the use of adjuvant
chemotherapy might beneﬁt survival [9].
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stone of treatment of PFTC for more than 15 years [74]. The addition
of a third cytotoxic drug, whether in triplet combinations or
sequential doublets, provides no beneﬁt [75]. However, improve-
ment might come through changes in scheduling, dose intensity, or
delivery [76], especially in light of the better survival in the Japa-
nese Gynecologic Oncology 3016 study [77] and its extensive trial
[74] than in conventional treatment, with a hazard ratio (HR) of
0.79 (95% CI 0.63e0.99, p ¼ 0.039). Very few data with regard to
PFTC can be extracted from the literature. Several authors using
cisplatin-based chemotherapy for patients with advanced-stage
PFTC reported overall response rates of 53e92% [53]. Data from
small series, including our previous report [9], showed the possible
value of cyclophosphamide, doxorubicin (epirubicin), and cisplatin
(the cyclophosphamide, adriamycin, and cisplatin, CAP or cyclo-
phosphamide, epirubicin, and cisplatin, CEP regimen). However,
based on domestic data, including ours (Table 1), we would favor
the use of a combination of platinum and a taxane as a choice for
patients with PFTC after complete resection of tumors, because a
trend toward improved survival was found in recent reports after
introducing the use of this combination.Outcomes
The 5-year disease-free or overall survival rate in the domestic
data ranged from 36% to 73% regardless of stages, whichwas similar
to other published data with reported survival ranging from 36% to
95% (Table 1). Possible reasons for this, in addition to the afore-
mentioned reasons, are improvements in surgical technique and
better teamwork [78e80], which result in a better chance of
optimal debulking surgerydcomplete tumor resection, which
might contribute to prolonged overall survival in patients with
PFTC.Conclusion
In conclusion, PFTC showed the following characteristics: (1) the
main type of PFTC was the serous type, often poorly differentiated;
(2) the diagnosis of PFTC is frequentlymissed or delayed; (3) PTFC is
often an earlier FIGO stage than is EOC, because of the appearance
of earlier but nonspeciﬁc symptoms or signs, such as abdominal
pain, vaginal bleeding, and watery discharge or mass; (4) the most
important clinicopathological prognostic factor was FIGO stage; (5)
the therapeutic strategy, which is often based on the guidelines for
treatment of EOC, and although still uncertain, includes an inten-
sive surgical effort such as complete surgical resection or optimal
cytoreductive surgery with minimal residual tumor, followed by
platinum-paclitaxel combination chemotherapy with/without tar-
geted therapy (for example, antiangiogenesis agents), which may
provide the best possibility of disease-free or improved overall
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